Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guizhou Sinorda Biomedicine Co., Ltd.
Guiyang, Guizhou, Chinaen.gzsnsw.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Linaprazan glurate (X842) approved for marketing in China for gastroesophageal reflux disease; SND002 (SLN-T) approved for Phase II in Europe for colorectal cancer with IIT results in solid tumors.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Small moleculeCell therapyOncolytic virusBispecific antibody
- Industry
- Biotech
02
Partnerships
Huadong Pharma (commercialization of Linaprazan Glurate)Porton Advanced (CDMO for cell therapies)Rigvir Group (ECHO-7 oncolytic virus licensing)
Beyond the preview
Go deeper on Guizhou Sinorda Biomedicine Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guizhou Sinorda Biomedicine Co., Ltd..